INTRODUCTION: Impaired vitamin K status in cystic fibrosis (CF) has been considered as a newly emerged pathogenetic factor for reduced bone mineral density (BMD). OBJECTIVES: Our aim was to evaluate the effectiveness of vitamin K supplementation in managing bone formation abnormalities in children and adolescents with CF. MATERIALS AND METHODS: The statuses of vitamins K and D in relation to biochemical markers of bone metabolism and BMD were examined in 20 CF children receiving vitamin D supplements but not vitamin K supplements. Laboratory tests were carried out at the beginning of the study period and after 1 year of vitamin K supplementation (10 mg single oral dose/week) and the results were compared; the results were also compared with those of 25 healthy controls. RESULTS AND DISCUSSION: Ten of the CF patients had BMD z-score<or=2.5 (n=5) or between -1 and -2.5 (n=5). Biochemical tests on patients before vitamin K supplementation revealed that the levels of osteoblastic activity markers, namely, bone alkaline phosphatase (BAP), serum osteocalcin (Gla-OC), serum carboxy-terminal propeptide of type I procollagen (PICP) and serum amino-terminal propeptide of type I procollagen (PINP), were significantly reduced compared with those of the controls. These patients had also lower 25-hydroxy-vitamin D (25(OH)D) and vitamin K serum levels, higher undercaboxylated osteocalcin (Glu-OC) and parathormone (PTH) levels and a higher calcium to creatinine ratio (Ca/Cr) than the controls. Vitamin K intake was associated with an increase in Gla-OC, PINP, PICP levels and a decrease in Glu-OC levels. PTH levels were lower after vitamin K supplementation without any difference in BMD z-scores. CONCLUSION: Our data indicate that vitamin K supplementation may have a beneficial role in bone health in CF children.
INTRODUCTION: Impaired vitamin K status in cystic fibrosis (CF) has been considered as a newly emerged pathogenetic factor for reduced bone mineral density (BMD). OBJECTIVES: Our aim was to evaluate the effectiveness of vitamin K supplementation in managing bone formation abnormalities in children and adolescents with CF. MATERIALS AND METHODS: The statuses of vitamins K and D in relation to biochemical markers of bone metabolism and BMD were examined in 20 CF children receiving vitamin D supplements but not vitamin K supplements. Laboratory tests were carried out at the beginning of the study period and after 1 year of vitamin K supplementation (10 mg single oral dose/week) and the results were compared; the results were also compared with those of 25 healthy controls. RESULTS AND DISCUSSION: Ten of the CF patients had BMD z-score<or=2.5 (n=5) or between -1 and -2.5 (n=5). Biochemical tests on patients before vitamin K supplementation revealed that the levels of osteoblastic activity markers, namely, bone alkaline phosphatase (BAP), serum osteocalcin (Gla-OC), serum carboxy-terminal propeptide of type I procollagen (PICP) and serum amino-terminal propeptide of type I procollagen (PINP), were significantly reduced compared with those of the controls. These patients had also lower 25-hydroxy-vitamin D (25(OH)D) and vitamin K serum levels, higher undercaboxylated osteocalcin (Glu-OC) and parathormone (PTH) levels and a higher calcium to creatinine ratio (Ca/Cr) than the controls. Vitamin K intake was associated with an increase in Gla-OC, PINP, PICP levels and a decrease in Glu-OC levels. PTH levels were lower after vitamin K supplementation without any difference in BMD z-scores. CONCLUSION: Our data indicate that vitamin K supplementation may have a beneficial role in bone health in CF children.
Authors: Robert M Aris; David A Ontjes; Sue A Brown; Worakij Chalermskulrat; Isabel Neuringer; Gayle E Lester Journal: Am J Respir Crit Care Med Date: 2003-11-01 Impact factor: 21.405
Authors: Steven P Conway; Susan P Wolfe; Keith G Brownlee; Helen White; Brian Oldroyd; John G Truscott; Julia M Harvey; Martin J Shearer Journal: Pediatrics Date: 2005-05 Impact factor: 7.124
Authors: D C Wilson; M Rashid; P R Durie; A Tsang; D Kalnins; M Andrew; M Corey; J Shin; E Tullis; P B Pencharz Journal: J Pediatr Date: 2001-06 Impact factor: 4.406
Authors: D S Donovan; A Papadopoulos; R B Staron; V Addesso; L Schulman; C McGregor; F Cosman; R L Lindsay; E Shane Journal: Am J Respir Crit Care Med Date: 1998-06 Impact factor: 21.405
Authors: Chiara Bertolaso; Veronique Groleau; Joan I Schall; Asim Maqbool; Maria Mascarenhas; Norma E Latham; Kelly A Dougherty; Virginia A Stallings Journal: J Pediatr Gastroenterol Nutr Date: 2014-04 Impact factor: 2.839
Authors: Nichole T Huffman; J Andrew Keightley; Cui Chaoying; Ronald J Midura; Dinah Lovitch; Patricia A Veno; Sarah L Dallas; Jeff P Gorski Journal: J Biol Chem Date: 2007-07-05 Impact factor: 5.157